Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
BCRX closed up 1.85 percent on Friday, February 16, 2018, on 1.12 times normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
|See historical BCRX trend table...|
|Date||Alert Name||Type||% Chg|
|Feb 16||200 DMA Resistance||Bearish||0.00%|
|Feb 16||50 DMA Resistance||Bearish||0.00%|
|Feb 16||Shooting Star Candlestick||Bearish||0.00%|
|Feb 16||Lizard Bearish||Bearish Day Trade Setup||0.00%|
|Feb 16||Wide Bands||Range Expansion||0.00%|
|Feb 15||Bearish Engulfing||Bearish||1.85%|
|Feb 15||Fell Below 50 DMA||Bearish||1.85%|
|Feb 15||Wide Bands||Range Expansion||1.85%|
|Feb 15||Overbought Stochastic||Strength||1.85%|
|Feb 14||200 DMA Resistance||Bearish||-2.94%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more BCRX news...
|52 Week High||9.25|
|52 Week Low||3.95|
|200-Day Moving Average||5.1428|
|50-Day Moving Average||5.0724|
|20-Day Moving Average||4.805|
|10-Day Moving Average||4.865|
|Average True Range||0.2944|
|Chandelier Exit (Long, 3 ATRs )||4.9168|
|Chandelier Exit (Short, 3 ATRs )||5.1332|
|Upper Bollinger Band||5.3217|
|Lower Bollinger Band||4.2883|
|Percent B (%b)||0.65|
|MACD Signal Line||-0.0918|
|Market Cap||398.92 Million|
|Num Shares||80.4 Million|
|Price-to-Earnings (P/E) Ratio||-8.00|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||5.50|
|Resistance 3 (R3)||5.53||5.39||5.41|
|Resistance 2 (R2)||5.39||5.25||5.37||5.38|
|Resistance 1 (R1)||5.17||5.16||5.28||5.14||5.35|
|Support 1 (S1)||4.81||4.89||4.92||4.78||4.57|
|Support 2 (S2)||4.67||4.80||4.65||4.54|
|Support 3 (S3)||4.45||4.67||4.51|
|Support 4 (S4)||4.42|